Journal
PHARMACOGENOMICS JOURNAL
Volume 13, Issue 3, Pages 235-241Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/tpj.2012.8
Keywords
genetic; genome; rheumatoid arthritis; tocilizumab
Categories
Funding
- Wellcome Trust [090532] Funding Source: Medline
Ask authors/readers for more resources
Rheumatoid arthritis (RA) is an immune-mediated inflammatory disease affecting the joints. A heterogeneous response to available therapies demonstrates the need to identify those patients likely to benefit from a particular therapy. Our objective was to identify genetic factors associated with response to tocilizumab, a humanized monoclonal antibody targeting the interleukin (IL)-6 receptor, recently approved for treating RA. We report the first genome-wide association study on the response to tocilizumab in 1683 subjects with RA from six clinical studies. Putative associations were identified with eight loci, previously unrecognized as linked to the IL-6 pathway or associated with RA risk. This study suggests that it is unlikely that a major genetic determinant of response exists, and it illustrates the complexity of performing genome-wide association scans in clinical trials.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available